Welcome to our dedicated page for Ekso Bionics news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics stock.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) is a developer of exoskeleton and rehabilitation technologies for medical and industrial applications, and its news flow reflects this focus. Company press releases highlight product and technology developments, capital markets activity, strategic partnerships, and financial performance. Ekso Bionics regularly describes itself as an industry leader in exoskeleton technology that supports or enhances human strength, endurance, and mobility, with an emphasis on improving health and quality of life.
News updates for EKSO often cover clinical and rehabilitation initiatives, such as the launch of eksoUniversity, a virtual platform offering continuing education courses for physical therapists and physical therapy assistants who work with patients with neurological conditions. Other announcements detail agreements like Ekso Bionics’ role as the exclusive authorized U.S. sales agent and distributor for MediTouch’s BalanceTutor rehabilitation system, which uses a patented 4D perturbation treadmill and multiple sensors to help patients with impaired balance respond to unexpected disturbances while walking.
Investors and observers can also find coverage of Ekso Bionics’ technology roadmap, including its acceptance into the NVIDIA Connect program and related efforts to build a proprietary foundation model for human motion and integrate AI-enabled capabilities into its Enterprise Health and Personal Health exoskeleton devices. The company has reported proof-of-concept for an AI voice agent, Ekso Voice Agent, designed for intelligent control of its legacy EksoNR device.
In addition, EKSO news includes quarterly financial results, reverse stock split announcements, registered direct offerings of common stock, and secured loan agreements. Together, these updates provide insight into the company’s operating trends, capital structure decisions, and strategic priorities. This news page aggregates such disclosures so readers can follow developments in Ekso Bionics’ exoskeleton, rehabilitation, and AI initiatives over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ekso Bionics Holdings (Nasdaq: EKSO) will announce its financial and business results for Q1 2023 on April 27, 2023. The release will take place after the close of trading, followed by a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results and recent developments. A live webcast will be available on the Company’s website, providing investors with real-time insights. This call presents an opportunity for stakeholders to engage with management regarding the company’s performance in the exoskeleton technology sector, which serves both medical and industrial markets. The replay of the call will also be accessible for one month post-event.
Ekso Bionics (Nasdaq: EKSO) has announced a significant collaboration with SoldierStrong, a non-profit focused on improving Veterans' lives through technology. SoldierStrong will donate an Ekso Indego Therapy device to the Spinal Cord Injury Unit at Augusta's Charlie Norwood VA Medical Center. This donation marks the 30th exoskeleton provided by SoldierStrong over the last decade, reaffirming their commitment to Veterans. The device is designed for individuals with spinal injuries and stroke, enabling them to stand and walk. A donation ceremony is scheduled for April 26, 2023, featuring a demonstration of the device, further emphasizing its clinical benefits. This partnership aims to deliver critical rehabilitation support, enhancing mobility for Veterans.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported its financial results for the year and quarter ending December 31, 2022. For the full year, revenue increased 15% to $12.9 million, driven by a rise in EksoHealth product sales. However, the fourth quarter saw a revenue decline to $3.6 million from $4.1 million in Q4 2021. Gross profit also fell to $1.7 million, reflecting a reduced gross margin of approximately 47%. The net loss for 2022 was $15.1 million, higher than the previous year's loss. As of year-end, the company had $20.5 million in cash, down from $40.4 million a year earlier.
Ekso Bionics (Nasdaq: EKSO) will announce its financial results for Q4 and the full year 2022 on March 28, 2023, after market close. A conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET, where management will discuss financial outcomes and recent business developments. Investors can access the live webcast on the company's website or call in directly. A replay of the webcast will be available for one month afterward. As a pioneer in exoskeleton technology, Ekso Bionics focuses on improving mobility and strength in medical and industrial sectors.
FAQ
What is the current stock price of Ekso Bionics (EKSO)?
What is the market cap of Ekso Bionics (EKSO)?
